Denali Therapeutics (DNLI) Long-Term Investments (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Long-Term Investments data on file, last reported at $63.8 million in Q1 2026.

• Quarterly Long-Term Investments fell 72.95% year-over-year to $63.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.8 million (down 72.95% YoY) and the FY2025 annual result came in at $98.3 million, down 72.64% from the prior year.
• Long-Term Investments fell to $63.8 million in Q1 2026 per DNLI's latest filing, from $98.3 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $490.7 million in Q1 2024 and bottomed at $7.9 million in Q3 2023.
• The 5-year median for Long-Term Investments is $167.1 million (2025), against an average of $216.7 million.
• The widest annual swing landed in 2024, when Long-Term Investments surged 5535.21%; it then slumped 94.45% in 2025.
• Tracing DNLI's Long-Term Investments over 5 years: stood at $94.2 million in 2022, then slumped by 91.61% to $7.9 million in 2023, then jumped by 4446.15% to $359.4 million in 2024, then tumbled by 72.64% to $98.3 million in 2025, then plunged by 35.13% to $63.8 million in 2026.
• Per Business Quant, the three latest DNLI Long-Term Investments figures stand at $63.8 million (Q1 2026), $98.3 million (Q4 2025), and $24.7 million (Q3 2025).

Peer Comparison